公开(公告)号：US12213998B2

公开(公告)日：2025-02-04

申请号：US17671479

申请日：2022-02-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eduardo Bravo ,  Maria Pascual

IPC: A61K35/35 ,  A61K35/28

Abstract: Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease.

公开(公告)号：US12188948B2

公开(公告)日：2025-01-07

申请号：US17728285

申请日：2022-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Daniel J. Sexton ,  Malini Viswanathan ,  Ryan Faucette ,  Tripti Gaur

IPC: G01N33/68 ,  G01N33/74 ,  G01N33/82 ,  G01N33/92 ,  G01N33/94

Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

公开(公告)号：US20250002868A1

公开(公告)日：2025-01-02

申请号：US18294941

申请日：2022-08-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Christian Fiedler ,  Dominik MITERGRADNEGGER ,  Meinhard HASSLACHER ,  Thomas GATTERNIG ,  Daniela VASINA ,  Michael FELDHOFER ,  Renate PFANDL

IPC: C12N7/00

Abstract: The present disclosure provides for a method of purifying adeno-associated virus comprising purifying full AAV capsids from a concentrated AAV fraction or preparation comprising empty AAV capsids and full AAV capsids. The present disclosure also provides for a method of purifying adeno-associated virus comprising purifying empty AAV capsids from a concentrated AAV fraction or preparation comprising empty AAV capsids and full AAV capsids. The method utilizes one or more monovalent and one or more divalent cations to effect the separation resulting in purified full AAV capsids or empty AAV capsids.

公开(公告)号：US20250001071A1

公开(公告)日：2025-01-02

申请号：US18689723

申请日：2022-09-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jack Lawrence Warren ,  Alexander David Norman ,  Merissa Lim Sarrias

IPC: A61M5/145 ,  A61M5/178 ,  A61M5/315

Abstract: An infusion pump may include automated syringe loading capabilities and/or medicinal fluid delivery capabilities to facilitate administration of medicinal fluids to a patient. The infusion pump may operate mechanically and may not require a power source to operate. The infusion pump may assist with filling a syringe with the medicinal fluid contents of one or more vials. The infusion pump may include a drug delivery assembly to deliver fluid at an adjustable but constant force. The infusion pump may permit the user to adjust the delivery rate continuously within a given range to improve comfort during infusion.

公开(公告)号：US12178981B2

公开(公告)日：2024-12-31

申请号：US16958388

申请日：2018-12-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki Murata ,  Shigeo Yanai

IPC: A61M37/00 ,  A61K41/00 ,  A61K49/22

Abstract: The present disclosure provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), the opening system containing a combination of (1) nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and (2) an ultrasound generating apparatus; a method for opening a BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.

公开(公告)号：US20240394881A1

公开(公告)日：2024-11-28

申请号：US18795513

申请日：2024-08-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Uday Veer Manish Bangia ,  Elliot Greenblatt ,  Daniel Alexander Leffler ,  Jenifer R.Q.W. Siegelman ,  Ozlem Nurcan Yardibi

IPC: G06T7/00 ,  G06F16/383 ,  G06F18/21 ,  G06T7/12 ,  G06T7/13 ,  G06V10/764 ,  G06V10/82

Abstract: Disclosed herein are computer-implemented method, system, and computer-program product (computer-readable storage medium) embodiments of image scoring for intestinal pathology. An embodiment includes receiving, via at least one processor, an output of an imaging device. The output of the imaging device may include a plurality of image frames forming at least a subset of a set of image frames depicting an inside surface of a digestive organ of a given patient; and decomposing, via at least one machine learning (ML) algorithm, at least one image frame of the plurality of image frames into a plurality of regions of interest. The at least one region of interest may be defined by determining that an edge value exceeds a predetermined threshold. At least one processor may automatically assign a first score based at least in part on the edge value for each region of interest and automatically shuffle the set of image frames.

公开(公告)号：US20240382482A1

公开(公告)日：2024-11-21

申请号：US18550571

申请日：2022-03-16

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nikolaos PAPAIOANNOU ,  Jeremy Mark TRAVINS ,  Sarah Jocelyn FINK ,  John Mark ELLARD ,  Alastair RAE ,  Jonathan Andrew SPENCER

IPC: A61K31/506 ,  C07D519/00

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

公开(公告)号：US20240374721A1

公开(公告)日：2024-11-14

申请号：US18292574

申请日：2022-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Chihiro Take ,  Gary Shapiro ,  Yoshiaki Kassai ,  Xingyue He ,  Chantal Kuhn

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783

Abstract: Disclosed herein are engineered immune cells that specifically recognizes mesothelin and expresses IL-15 and optionally CCL19. Also disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin, and a 4-IBB intracellular region; and a polynucleotide encoding IL-15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules, and methods of using the engineered immune cells.

公开(公告)号：US12135329B2

公开(公告)日：2024-11-05

申请号：US18308813

申请日：2023-04-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jiang Wu ,  Guodong Zhang ,  Daniel J. Sexton ,  Ryan Faucette ,  Gul M. Mustafa ,  Mark Szewc

IPC: G01N33/68 ,  G01N30/72 ,  G01N30/88 ,  G01N30/02

Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.

公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC: A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

Abstract: This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.